⚠️ Educational purposes only. PeptideIQ does not constitute medical advice, diagnosis, or treatment. Peptide therapy should only be pursued under the guidance of a licensed medical provider. Many peptides discussed are research-grade compounds not approved by the FDA. Always verify current legal status in your jurisdiction before use.
← Back to library
Semaglutide
Semaglutide (Ozempic / Wegovy)
Strong RCTFDA Approved
An FDA-approved GLP-1 receptor agonist with the strongest clinical evidence for weight loss of any peptide — 15–18% body weight reduction in trials.
Mechanism of action
GLP-1 receptor agonism, appetite suppression, slowed gastric emptying, insulin regulation
Primary benefits
- ✓15-18% body weight reduction
- ✓Appetite suppression
- ✓Blood sugar regulation
- ✓Cardiovascular benefits
- ✓Reduced cravings
Dosing
Beginner
0.25 mg/week (weeks 1-4)
Intermediate
0.5-1 mg/week
Advanced
2.4 mg/week (Wegovy max dose)
Frequency: Once weekly
Timing: Same day each week, any time of day
Route: Subcutaneous injection
Cycling protocol
Duration
16-20 weeks minimum
Pattern
Weekly titration upward
Break after
Ongoing under medical supervision
Important warnings
- ⚠️Prescription only
- ⚠️Nausea common during titration
- ⚠️Contraindicated with personal or family history of thyroid cancer
- ⚠️Compounded versions restricted as of March 2025